The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine.
This might not be enough to turn around the fortunes of the developer of go-to COVID-19 vaccine Spikevax, however.
Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock. Investors piled into its shares over the week, sending it to a more than 12% gain over the period, according to data compiled by S&P Global Market Intelligence. Positive news from the lab was a significant factor in this.
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical trial the vaccine, developed using Moderna’s signature mRNA-based approach, produced a more robust immune response than a standard flu jab currently available on the market.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
That surely came as a relief to Moderna investors, since the company’s latest stock-rattling news was its withdrawal of a Food and Drug Administration application for a combination COVID-19/flu vaccine in May. At the time, the company pledged to submit a new application based on efficacy data from the stand-alone trial.
Along with the latest findings for mRNA-1010, Moderna said that it would also resubmit its application for the combination vaccine.
As for the flu shot alone, in the press release detailing the trial’s results the company quoted CEO Stéphane Bancel as saying that they “are a significant milestone in our effort to reduce the burden of influenza in older adults.”
Although this latest development is the good news Moderna shareholders have been waiting for quite some time to receive, I personally don’t think it makes the company’s stock a buy in and of itself, as I can’t imagine a new flu vaccine will light the world on fire.
Having said that, Moderna does have an admirably loaded slate of development programs, so if one or several show promise the shares might become more enticing.
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $699,558!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $976,677!*
Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of June 30, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
